Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $91.93M
• Dividend Yield: N/A
• Average Volume (3M): 209.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: -98.25%
• EPS Growth: 63.05%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,335,992
• 10 Day Avg. Volume: 60,839
• 30 Day Avg. Volume: 209,481
• PEG Ratio: <0.01
• Price to Book (P/B): -1.26
• Price to Sales (P/S): 248.45
• P/FCF Ratio: -0.79
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 343.58
• Enterprise Value/Gross Profit: 343.58
• Enterprise Value/Ebitda: -1.09
• 1Y Price Target: $19.00
• Price Target Upside: 195.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $9.00 ▲(39.75% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with negative equity). Technicals are a notable offset with strong momentum above major moving averages, but overbought signals add near-term risk; valuation remains challenged due to negative earnings and no dividend support.

Positive Factors

Clinical progress and indication expansion

Robust early responses from paxalisib combination in metastatic TNBC indicate the drug may have activity beyond brain cancers. If confirmed in planned expansions, this durable clinical signal broadens the addressable market, increases strategic partnering and licensing optionality, and materially strengthens long-term commercial prospects.

Material financing extends runway

Securing ~$46.5M net proceeds provides multi-year funding to advance clinical programs and reduces the immediate need for dilutive raises. This enhances execution certainty for trials and regulatory milestones over the next 2-3 years and signals investor willingness to underwrite the development plan.

Maintained Nasdaq listing

Regaining compliance and avoiding delisting preserves U.S. capital-market access, liquidity and investor visibility. This structural outcome lowers regulatory overhang, sustains the company’s ability to raise further funds and strike collaborations from a credible public listing platform.

Negative Factors

Minimal and volatile revenue with large losses

The company generates almost no recurring revenue while incurring large operating losses, meaning commercial self-sustainability is distant. Persistent negative profitability increases dependency on external capital and raises execution risk for long-term trials and development programs.

Negative equity and shrinking asset base

Negative shareholders’ equity and a dramatically smaller asset base reflect accumulated losses and capital erosion. This structural weakness reduces financial flexibility, may constrain collateral for agreements, and heightens vulnerability to adverse funding or trial setbacks.

Consistent cash burn and funding reliance

Persistent negative operating and free cash flow indicate the business cannot self-fund development and will require future capital raises. Reliance on external financing is a durable risk that can dilute shareholders, delay programs if markets tighten, and affect long-term strategic choices.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Kazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary

Financials are very weak: revenue is extremely small and volatile (down to ~$42K in 2025 from ~$2.3M in 2024), losses remain large (net loss ~$20.7M in 2025), and operating/free cash flow are consistently negative (FCF about -$13.3M in 2025). Low absolute debt helps, but negative equity and a shrinking asset base materially raise funding and execution risk.

Income Statement

The revenue base is extremely small and volatile, with annual revenue dropping to ~$42K in 2025 from ~$2.3M in 2024 (sharp contraction after a prior spike). Profitability remains deeply negative: EBIT and net income are consistently large losses (e.g., net loss of ~$20.7M in 2025 and ~$26.8M in 2024), indicating ongoing high operating spend relative to revenue. A key positive is that gross profit equals revenue in the periods shown, but the business is still far from covering operating costs.

Balance Sheet

Leverage is low in absolute terms (total debt ~ $0.4M in 2025, down from ~$0.6M in 2024), which reduces near-term balance sheet risk from creditors. However, equity has turned negative (stockholders’ equity of about -$8.3M in 2025 and -$10.0M in 2024), which is a meaningful weakness and reflects accumulated losses and capital erosion. Total assets also fell materially (to ~$6.1M in 2025 from ~$21.6M in 2024), pointing to a shrinking balance sheet and potentially reduced financial flexibility.

Cash Flow

Cash generation remains a clear weakness: operating cash flow and free cash flow are consistently negative across all years shown, including about -$13.3M in 2025 and -$9.6M in 2024, implying continued cash burn to fund operations. Free cash flow improved versus 2024 (as indicated by positive free cash flow growth in 2025), but the company is still reliant on external funding to sustain operations. The pattern over multiple years suggests limited self-funding capacity until revenue scales materially or costs are reduced.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	42.00K	2.31M	555.00	10.00K	15.18M
Gross Profit	42.00K	2.31M	555.00	10.00K	15.18M
EBITDA	-13.28M	-26.59M	-22.28M	-23.52M	-5.11M
Net Income	-20.70M	-26.78M	-20.47M	-25.01M	-8.42M
Balance Sheet
Total Assets	6.06M	21.59M	28.08M	35.89M	58.09M
Cash, Cash Equivalents and Short-Term Investments	4.34M	1.66M	5.24M	7.36M	27.59M
Total Debt	396.00K	634.00K	1.80M	1.84M	0.00
Total Liabilities	14.36M	31.60M	16.03M	17.61M	20.24M
Stockholders Equity	-8.30M	-10.02M	12.05M	18.27M	37.85M
Cash Flow
Free Cash Flow	-13.28M	-9.58M	-15.16M	-22.76M	-9.11M
Operating Cash Flow	-13.28M	-9.58M	-15.16M	-22.76M	-9.11M
Investing Cash Flow	0.00	0.00	0.00	-2.37M	0.00
Financing Cash Flow	15.98M	5.99M	12.97M	3.73M	28.11M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Positive. The current price of 6.44 is below the 20-day moving average (MA) of 7.14, below the 50-day MA of 6.78, and below the 200-day MA of 7.75, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 58.51 is Neutral, neither overbought nor oversold. The STOCH value of 45.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLTO	56 Neutral	$1.59B	-0.39	-134.39%	―	―	37.42%
PHIO	53 Neutral	$14.64M	-1.29	-107.58%	―	―	83.95%
MRKR	53 Neutral	$22.84M	-1.87	-92.35%	―	-12.99%	-13.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KZIA	49 Neutral	$91.93M	-0.50	337.03%	―	-98.25%	63.05%
RNAZ	49 Neutral	$8.78M	-0.46	-684.86%	―	―	96.75%
XTLB	39 Underperform	$6.39M	-5.80	―	―	―	65.45%

Kazia Therapeutics Corporate Events

Kazia Therapeutics Posts Early Efficacy Signals for Paxalisib Combo in Metastatic Triple-Negative Breast Cancer

On January 27, 2026, Kazia Therapeutics reported encouraging early clinical signals from an ongoing Phase 1b trial of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer, initiated in June 2025, with two of two evaluable trial patients achieving partial responses and a separate expanded-access patient demonstrating a confirmed complete metabolic response. The company said responses occurred in heavily burdened patients with visceral and multi-organ disease, treatment duration has reached a median of roughly 6.1 months with all patients remaining on therapy, and safety at the 30 mg daily dose appears manageable with mostly mild to moderate adverse events, findings that, if confirmed in the planned expansion of study sites through 2026 and additional breast cancer cohorts, could enhance paxalisib’s profile beyond brain cancers and potentially strengthen Kazia’s position in the highly competitive immuno-oncology and breast cancer treatment landscape.

The most recent analyst rating on (KZIA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance

On December 18, 2025, Kazia Therapeutics Limited regained compliance with Nasdaq’s continued listing standards by meeting the alternative minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1), after previously being notified on November 12, 2025 that it had failed to satisfy the $35 million market value of listed securities threshold by November 10, 2025. As a result, a Nasdaq hearing that had been scheduled for January 8, 2026 to address potential suspension or delisting was cancelled, and Nasdaq confirmed that Kazia’s ADSs will continue trading on the Nasdaq Capital Market, removing an immediate overhang of listing risk for the company and its investors.

The most recent analyst rating on (KZIA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium

On December 10, 2025, Kazia Therapeutics announced promising new data from the San Antonio Breast Cancer Symposium regarding their drug paxalisib. The findings demonstrate paxalisib’s ability to reinvigorate anti-tumor immunity in advanced breast cancer populations, including TNBC and HER2+. The data, derived from advanced liquid biopsy profiling and immune phenotyping, suggest that paxalisib can disrupt aggressive circulating tumor cell clusters and enhance responsiveness to immunotherapy. This positions paxalisib as a potentially transformative agent in breast cancer treatment, offering new therapeutic opportunities beyond current HER2-targeted therapies and checkpoint inhibitors.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance

On December 2, 2025, Kazia Therapeutics Limited entered into Securities Purchase Agreements with institutional and accredited purchasers for a private placement of equity securities, raising approximately $46.5 million. This financial move was aimed at addressing the company’s compliance with Nasdaq’s listing standards, following a staff determination letter received on November 12, 2025, indicating the company’s market value was below the required minimum. The successful private placement is expected to enhance Kazia’s stockholders’ equity, potentially aiding in regaining compliance with Nasdaq’s requirements, although there is no guarantee of the outcome.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development

On December 2, 2025, Kazia Therapeutics announced a $50 million private placement of equity securities with institutional and accredited investors, expected to close by December 3, 2025. The net proceeds of approximately $46.5 million will be used to further clinical development of their lead program, paxalisib, and other corporate purposes, extending the company’s cash runway into the second half of 2028. This strategic financial move is set to bolster Kazia’s position in the oncology drug development sector, supporting its ongoing trials and potential market expansion.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.